{
  "nctrialId": "HC-1535",
  "title": "A  Double-Blind, Placebo-Controlled Multi-Center Study of AST-611 (anti-IL-5 antibody) in Patients With Irritable Bowel Syndrome",
  "officialTitle": "A  Double-Blind, Placebo-Controlled Multi-Center Study of AST-611 (anti-IL-5 antibody) in Patients With Irritable Bowel Syndrome",
  "sponsor": "Canadian Blood Services",
  "indication": "Irritable Bowel Syndrome",
  "phase": "Phase 4",
  "fileName": "HC-1535.json",
  "fileSize": 140859,
  "date": "2023-12-16",
  "completionDate": "2027-02-12",
  "drugName": "AST-611 (anti-IL-5 antibody)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a  double-blind, placebo-controlled multi-center study designed to evaluate the efficacy and safety of AST-611 (anti-IL-5 antibody) in patients with Irritable Bowel Syndrome. The study will enroll approximately 450 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 24-77 years\n- Confirmed diagnosis of Irritable Bowel Syndrome\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}